Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;44(12):2711-2725.
doi: 10.1007/s00296-024-05722-1. Epub 2024 Sep 23.

Biological therapy for psoriatic arthritis: current state and future perspectives

Dominika Boboryko  1 , Joanna Olejnik-Wojciechowska  1 , Magdalena Baranowska  1 , Aleksandra Wiktoria Bratborska  2 , Patryk Skórka  1 , Andrzej Pawlik  3
Affiliations
Review

Biological therapy for psoriatic arthritis: current state and future perspectives

Dominika Boboryko et al. Rheumatol Int. 2024 Dec.

Abstract

Psoriatic arthritis is a medical condition that lies at the intersection of various fields of medicine, and its therapy always requires a comprehensive, holistic approach. Biological disease-modifying antirheumatic drugs (bDMARDs) constitute an extremely effective treatment method for PsA, provided that appropriate principles for patient qualification for the drug are followed, along with subsequent monitoring of the response to treatment. Based on their mechanisms of action, four main groups of bDMARDs used in PsA can be distinguished (TNF inhibitors, IL-12/23 and IL-23 inhibitors, IL-17 inhibitors, CTLA4 agonists). Clinical trials are ongoing in search of registration for additional bDMARDs, and the tasks for doctors and scientists worldwide include patient education, increasing treatment accessibility, and optimizing its costs.

Keywords: Biological disease-modifying antirheumatic drugs; Biological treatment; Janus kinase inhibitors; Psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Disclaimer: The authors state that no part of this narrative review is copied or published elsewhere, in whole or in part, in any language. Conflict of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

References

    1. van de Kerkhof PC (2022) From empirical to pathogenesis-based treatments for Psoriasis. J Invest Dermatol 142(7):1778–1785 - PubMed
    1. Nestle FO, Kaplan DH, Barker J, Psoriasis (2009) N Engl J Med 361(5):496–509 - PubMed
    1. Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, Gisondi P, Balint PV, Bertheussen H, Boehncke WH, Damjanov NS, De Wit M, Errichetti E, Marzo-Ortega H, Protopopov M, Puig L, Queiro R, Ruscitti P, Savage L, Schett G, Siebert S, Stamm TA, Studenic P, Tinazzi I, Van Den Bosch FE, Mil A, Watad A, Smolen JS, McGonagle DG (2023) EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. ard-2023-224148.
    1. Su YJ (2020) Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing. Clin Rheumatol 39(12):3677–3684 - PubMed - PMC
    1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673 - PubMed

MeSH terms

Substances

LinkOut - more resources